Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
VIELA BIO, INC. has 7 pending office actions in Biotechnology & Pharmaceuticals. The docket involves 6 examiners and 4 art units, indicating both examiner dispersion and repeated activity within some technical groupings. DAHLE, CHUN WU is the busiest examiner, with 2 pending matters.
The concentration with DAHLE, CHUN WU gives counsel a useful point for identifying potentially consistent examination issues, but the remaining matters are distributed among other examiners. A portfolio review should therefore distinguish recurring technical or claim themes from examiner-specific positions.
Because the active matters are routed through multiple art units, centralized tracking can support consistent disclosure and amendment choices without assuming that one response will resolve issues across the docket. Examiner history should be reviewed separately for each assigned application.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLE, CHUN WU | 2 | 50.2% | +51.1% |
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
| WEN, SHARON X | 1 | 56.8% | +32.6% |
| SULLIVAN, DENNIS JOHN | 1 | 57.6% | +48.0% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615679 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | DAHLE, CHUN WU | 5d overdue |
| 18559195 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS | WEN, SHARON X | — |
| 17606306 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | LEE, YIE CHIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | DAHLE, CHUN WU | 5d overdue |
| 18147287 | METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER | WANG, CHANG YU | 63d |
| 18615679 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS | LANDSMAN, ROBERT S | — |
| 18415031 | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE | DAHLE, CHUN WU | — |
| 18559195 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS | WEN, SHARON X | — |
| 18558505 | METHODS OF TREATMENT OF AUTOIMMUNE DISORDERS USING ILT7 BINDING PROTEINS | SULLIVAN, DENNIS JOHN | — |
| 17606306 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | LEE, YIE CHIA | — |
| Art Unit | Apps |
|---|---|
| 1641 | 3 |
| 1642 | 2 |
| 1647 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18615679 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS | LANDSMAN, ROBERT S | 1647 | §103§112DP | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18415031 | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE | DAHLE, CHUN WU | 1641 | §112Other | Non-Final OA | — | Pending | Jan 17, 2024 |
| 18559195 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS | WEN, SHARON X | 1641 | §103§112 | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18558505 | METHODS OF TREATMENT OF AUTOIMMUNE DISORDERS USING ILT7 BINDING PROTEINS | SULLIVAN, DENNIS JOHN | 1642 | §103§112DPOther | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | DAHLE, CHUN WU | 1641 | §102§103§112 | Final Rejection | 5d overdue | Pending | Apr 19, 2023 |
| 18147287 | METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER | WANG, CHANG YU | 1675 | §103 | Non-Final OA | 63d | Pending | Dec 28, 2022 |
| 17606306 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | LEE, YIE CHIA | 1642 | §103§112Other | Non-Final OA | — | Pending | Oct 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVIELA BIO, INC. has 7 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
Chun Wu Dahle has the most, with 2 of VIELA BIO, INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
